The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US […]
Coronary/Structural Heart
Shineco, Inc. Subsidiary Receives Prior Approval Supplement from the NMPA Jiangsu Bureau for the Marketing Approval of “Cardiac 5-Minute Test”
BEIJING, Dec. 19, 2022 (GLOBE NEWSWIRE) — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company’s controlled affiliate Changzhou Biowin Pharmaceutical Co., Ltd. (“CBP”) has received the Prior Approval Supplement from the Jiangsu […]
Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States
SINGAPORE, Dec. 16, 2022 /PRNewswire/ — Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays. The use of small peptides, conjugated with gold nanoparticles, allows a […]
ELECTRODUCER ANNOUNCES THE PUBLICATION OF POSITIVE RESULTS FROM ITS PILOT STUDY IN EUROINTERVENTION MEDICAL JOURNAL
The first of its kind study involved 60 patients and confirmed Electroducer Sleeve® as a safe and effective treatment for heart diseases The company plans to launch its device in the US market by the end of 2023, followed by the European market in 2024 Grenoble, France, December 15, 2022 – Electroducer, […]
Valo Health – FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure
Findings Part of Five-Year Research Collaboration Between Valo and FDA Developed on Valo’s Biowire Platform BOSTON, Dec. 14, 2022 /PRNewswire/ — Valo Health, Inc (“Valo”) shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo’s Biowire platform to predict clinical efficacy of Cardiac […]
Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal […]
Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex
The peer-reviewed publication shows 81% lower heart failure hospitalizations per year and a 48% decrease in rehospitalizations from the national average at 30 days MINNEAPOLIS, Dec. 13, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today […]
A New Study From Hello Heart Shows Surprising Findings on Walking Patterns and Heart Health
Correlations between lifestyle changes and blood pressure indicate how a person could increase their walking to positively impact heart health MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced new data on how minor lifestyle and behavioral changes can have a significant […]
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran)
– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis – […]
Provident Healthcare Partners Advises Southwest Cardiovascular Associates in its Partnership with Cardiovascular Associates of America
BOSTON and NEW YORK, Dec. 8, 2022 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Southwest Cardiovascular Associates (“SWCVA” or “Company”) in its partnership with Cardiovascular Associates of America (“CVAUSA”), a portfolio company of Webster Equity Partners. SWCVA provides interventional and diagnostic cardiology services throughout its three-location footprint […]



